Tesamorelin
Egrifta
A stabilized growth-hormone-releasing hormone (GHRH) analog that binds pituitary GHRH receptors to stimulate endogenous growth hormone secretion. FDA-approved (Egrifta) to reduce excess visceral abdominal fat in HIV-associated lipodystrophy.
Half-life
~26-38 min, subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Supplied lyophilized; reconstitute with sterile water; refrigerate the finished product and protect from light.
References
- FDA label: Egrifta (2010)
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.